PUBLIC COMPANY
save$ACADACADIA PHARMACEUTICALS INC
$ACAD19.95+0.30%San Diego, CA, USupdated 1d ago
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
community read0 votes
pipeline
5
marketed
2
phase 3
1
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 32Marketed2Unknown
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase2Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
- phase3Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
- phase2ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- phase3OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
- phase3ACP-204 in Adults With Alzheimer's Disease Psychosis
- phase3ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
- phase3Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
- phase3Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
🐶 Hiring Signal
next earnings Nov 4, 2026
News
- Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s dataNovo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.biopharma_dive · 8d ago
- Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3Acadia Pharmaceuticals reported a Phase 2 failure in Alzheimer’s disease psychosis, but the company said it saw enough signal to continue forward into Phase 3 — with a caveat. The biotech’s experim…endpoints · 9d ago
- Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forwardWhile Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy bod…biospace · 9d ago
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuingAcadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…fiercebiotech · 10d ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 1mo ago
- On second try, Acadia drug gets nod from European regulatorsThe influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.biopharma_dive · 3mo ago
- Celiac disease is entering a new era of therapeutic innovationFor the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.biopharma_dive · 3mo ago
- Rapport ‘fully prepared’ to launch seizure drug solo, CEO saysIn a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.biopharma_dive · 3mo ago
- Reigniting Your Curiosity During FellowshipMegan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.onclive · 4mo ago
Data sources
last refreshed 57m ago
Found something off?
comments(0)
5-min edit window · permanent after that